• Emmanouil Pikoulis, Georgios A Margonis, Nikolaos Andreatos, Kazunari Sasaki, Anastasios Angelou, Georgios Polychronidis, Anastasia Pikouli, Elena Riza, Timothy M Pawlik, and Efstathios Antoniou.
• First Department of Surgery, Laiko Hospital, University of Athens, Athens, Greece.
• Anticancer Res. 2016 Sep 1; 36 (9): 4805-11.

Background/AimsThe impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM.Materials And MethodsA structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection.ResultsEight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively.ConclusionBRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered.Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

26 keywords...

hide…